Sweden · Delayed Price · Currency is SEK Genovis AB (publ.) Statistics
Total Valuation
STO:GENO has a market cap or net worth of SEK 1.35 billion. The enterprise value is 1.27 billion.
| Market Cap | 1.35B |
| Enterprise Value | 1.27B |
Important Dates
The last earnings date was Thursday, July 23, 2026.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:GENO has 67.46 million shares outstanding. The number of shares has increased by 1.12% in one year.
| Current Share Class | 67.46M |
| Shares Outstanding | 67.46M |
| Shares Change (YoY) | +1.12% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 16.10% |
| Owned by Institutions (%) | 32.74% |
| Float | 56.60M |
Valuation Ratios
The trailing PE ratio is 64.76 and the forward PE ratio is 44.29. STO:GENO's PEG ratio is 27.01.
| PE Ratio | 64.76 |
| Forward PE | 44.29 |
| PS Ratio | 9.87 |
| PB Ratio | 4.39 |
| P/TBV Ratio | 7.71 |
| P/FCF Ratio | 28.21 |
| P/OCF Ratio | 26.42 |
| PEG Ratio | 27.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 63.25, with an EV/FCF ratio of 26.43.
| EV / Earnings | 61.84 |
| EV / Sales | 9.25 |
| EV / EBITDA | 63.25 |
| EV / EBIT | 63.25 |
| EV / FCF | 26.43 |
Financial Position
The company has a current ratio of 5.76, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.76 |
| Quick Ratio | 4.44 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 3.59 |
| Debt / FCF | 1.50 |
| Interest Coverage | 4.93 |
Financial Efficiency
Return on equity (ROE) is 7.50% and return on invested capital (ROIC) is 10.15%.
| Return on Equity (ROE) | 7.50% |
| Return on Assets (ROA) | 4.09% |
| Return on Invested Capital (ROIC) | 10.15% |
| Return on Capital Employed (ROCE) | 5.11% |
| Weighted Average Cost of Capital (WACC) | 13.39% |
| Revenue Per Employee | 3.26M |
| Profits Per Employee | 487,976 |
| Employee Count | 36 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, STO:GENO has paid 4.53 million in taxes.
| Income Tax | 4.53M |
| Effective Tax Rate | 18.11% |
Stock Price Statistics
The stock price has decreased by -32.46% in the last 52 weeks. The beta is 1.75, so STO:GENO's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | -32.46% |
| 50-Day Moving Average | 19.54 |
| 200-Day Moving Average | 19.89 |
| Relative Strength Index (RSI) | 50.52 |
| Average Volume (20 Days) | 48,967 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:GENO had revenue of SEK 136.99 million and earned 20.50 million in profits. Earnings per share was 0.31.
| Revenue | 136.99M |
| Gross Profit | 121.54M |
| Operating Income | 24.93M |
| Pretax Income | 25.03M |
| Net Income | 20.50M |
| EBITDA | 20.04M |
| EBIT | 20.04M |
| Earnings Per Share (EPS) | 0.31 |
Balance Sheet
The company has 157.19 million in cash and 71.97 million in debt, with a net cash position of 85.22 million or 1.26 per share.
| Cash & Cash Equivalents | 157.19M |
| Total Debt | 71.97M |
| Net Cash | 85.22M |
| Net Cash Per Share | 1.26 |
| Equity (Book Value) | 308.00M |
| Book Value Per Share | 4.57 |
| Working Capital | 168.40M |
Cash Flow
In the last 12 months, operating cash flow was 51.19 million and capital expenditures -3.24 million, giving a free cash flow of 47.95 million.
| Operating Cash Flow | 51.19M |
| Capital Expenditures | -3.24M |
| Depreciation & Amortization | 8.00M |
| Net Borrowing | -572,000 |
| Free Cash Flow | 47.95M |
| FCF Per Share | 0.71 |
Margins
Gross margin is 88.73%, with operating and profit margins of 18.20% and 14.96%.
| Gross Margin | 88.73% |
| Operating Margin | 18.20% |
| Pretax Margin | 18.27% |
| Profit Margin | 14.96% |
| EBITDA Margin | 13.83% |
| EBIT Margin | 13.83% |
| FCF Margin | 35.00% |
Dividends & Yields
STO:GENO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.12% |
| Shareholder Yield | -1.12% |
| Earnings Yield | 1.52% |
| FCF Yield | 3.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for STO:GENO is 32.00, which is 58.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 32.00 |
| Price Target Difference | 58.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 20.50% |
| EPS Growth Forecast (3Y) | 34.20% |
Stock Splits
The last stock split was on April 4, 2012. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 4, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |